0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Adynxx
Its shares trade under the ticker ADYX. It has been listed since 12 October 1998. In the fiscal year to 31 December 2018, it reported revenue of $2.2m and a net loss of $8.4m. At that date it held total assets of $9.7m and shareholders' equity of $8.3m.
Adynxx, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in San Francisco, California. The firm is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Oct 1998
- Employees
- 6
- Website
- alliqua.com ↗
Leadership
Pay as last reported
- Mr. Dennis PodlesakChairman of the Board
- Mr. Rick OrrChief Executive Officer, Principal Financial Officer, Director, since 2019
- Dr. Julien MametChief Scientific Officer, Director, since 2019
- Dr. Donald ManningChief Medical Officer
- Mr. Stan AbelDirector
- Mr. Gregory FlesherDirector
- Mr. Matthew RuthDirector
- Dr. Eckard WeberDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Adynxx Inc has several strengths that contribute to its success in the market. Firstly, the company possesses a highly skilled and experienced team of researchers and scientists who are dedicated to the development of innovative medical solutions. This expertise enables Adynxx to stay at the forefront of its field and deliver cutting-edge products to customers.
- Additionally, Adynxx Inc has established strong collaborations with renowned medical institutions, which grants them access to valuable resources and research capabilities. This network helps the company strengthen its product development pipeline and ensures the introduction of high-quality products to the market.
- Furthermore, Adynxx Inc boasts a robust intellectual property portfolio consisting of numerous patents and trademarks. This not only provides the company with a competitive advantage but also safeguards its inventions from being replicated or imitated by competitors.
Weaknesses
- Despite its strengths, Adynxx Inc faces certain weaknesses that could hinder its growth. One weakness is the limited financial resources available to the company. This may restrict the speed of product development and hinder the overall expansion of the business.
- Another weakness lies in the company's limited market presence. While Adynxx has made significant strides in its research and development activities, it may struggle to establish a significant market share due to the intense competition and saturation in the medical solutions industry.
Opportunities
- Adynxx Inc has identified several opportunities that could propel its growth in the future. One opportunity lies in the increasing demand for innovative pain management solutions. With a focus on developing non-opioid alternatives, Adynxx is well-positioned to capture a significant share of the market and cater to the evolving needs of patients and healthcare professionals.
- Additionally, the company can explore strategic partnerships with pharmaceutical companies or medical device manufacturers to leverage their distribution networks and enhance market reach. This could open doors for Adynxx Inc to penetrate new markets and increase its customer base.
Threats
- Adynxx Inc faces certain threats that may impact its operations and market position. One major threat is the stringent regulatory environment surrounding the development and commercialization of medical solutions. The company must ensure compliance with regulatory guidelines and overcome any potential hurdles in obtaining necessary approvals for its products.
- Moreover, competition from both established players and emerging startups poses a significant threat to Adynxx's market share. The industry's fast-paced nature and constant technological advancements require the company to stay agile and innovative to maintain a competitive edge.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.